JPS6121947B2 - - Google Patents
Info
- Publication number
- JPS6121947B2 JPS6121947B2 JP59052439A JP5243984A JPS6121947B2 JP S6121947 B2 JPS6121947 B2 JP S6121947B2 JP 59052439 A JP59052439 A JP 59052439A JP 5243984 A JP5243984 A JP 5243984A JP S6121947 B2 JPS6121947 B2 JP S6121947B2
- Authority
- JP
- Japan
- Prior art keywords
- phenoxy
- butyric acid
- chlorobenzyl
- column
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 5
- 229960001214 clofibrate Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007038 hydrochlorination reaction Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- UXIVINXAZVEIMC-UHFFFAOYSA-N methyl 2-(4-chlorophenoxy)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 UXIVINXAZVEIMC-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- VKNSAVOURPMBRN-UHFFFAOYSA-N pyridin-3-ylmethyl 2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutanoate Chemical compound C=1C=CN=CC=1COC(=O)C(C)(CC)OC(C=C1)=CC=C1CC1=CC=C(Cl)C=C1 VKNSAVOURPMBRN-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は、２−メチル−２−〔４−（4′−クロル
ベンジル）−フエノキシ〕−酪酸−（３−オキシメ
チルピリジン）−エステル−塩酸塩なる新規の脱
コレステロール化合物を、一般式
〔式中、Halはハロゲン原子を意味する。〕で表わ
される２−メチル−２−〔４−（4′−クロルベンジ
ル）−フエノキシ〕−酪酸ハロゲニドと３−ヒドロ
キシ−メチルピリジンとの反応およびその生成物
の塩酸塩化によつて製造する方法に関する。
この化合物がコレステロール濃度低減剤として
予期し得なかつた有利な性質を有することが判明
した。アリールオキシカルボン酸エステルは血液
の、高くなりすぎたコレステロール及びトリグリ
シド含有量の治療に使用することが出来ることは
英国特許第860303号明細書にて公知である。本発
明の化合物は、上記英国特許に開示されていない
ものである。
英国特許第860303号明細書に記載されている一
化合物、即ち２−（4′−クロルフエノキシ）−イソ
酪酸メチルエステル〔WHO（世界保健機構）に
よりクロフイブラート（clofibrat）と呼称され
た〕は爾来人類の医学に於て著るしく重要のもの
となつた。本発明の新規化合物は、このクロフイ
ブラートよりも、驚ろく程に著しく勝つていると
いうことが判明した。
後記表には動物実験に就いての結果を示した
が、これはクロフイブラートと比較して得られた
結果である。この表の欄(1)にはこの試験物質の識
別番号を記載した。欄(2)には試験物質名を記し
た。欄(3)と欄(4)の数字はそれぞれ、試験動物の体
重１Kg当りのmg数で表示した、試験物質の経口投
与量（mg/Kg）である。欄(3)にはマウスに対する
急性毒性LD50が記載されている。欄(4)にはラツ
トに於ける血清コレステロール濃度を25％だけ低
下させる一日の投与量が記載されている
（ED25）。欄(5)には上記の欄の数値から得られた
治療係数、即ちLD50／ED25なる商が記載されて
いる。
欄(4)の数値を測定するために、正常に飼育した
雄のラツト８ないし10匹からなる用量群が、アラ
ビアゴムで懸濁させた試験物質で毎日１回10日間
治療された。全コレステロール含量の測定はリヒ
テリツヒ（RICHTERICH：クリニツシエ・ヘミ
ー、S.Karger Basel／ニユーヨーク1965年第232
頁）に従つた。アラビアゴムだけで治療した対照
群に対しての、段々に減らして投与した製剤群に
於ける群平均値の百分率変化から用量−作用曲線
が半ロガリズム座標用紙上に描かれたそしてそれ
からED25が読みとられた。
The present invention provides a novel decholesterol compound, 2-methyl-2-[4-(4'-chlorobenzyl)-phenoxy]-butyric acid-(3-oxymethylpyridine)-ester-hydrochloride, which has the general formula [In the formula, Hal means a halogen atom. 2-Methyl-2-[4-(4'-chlorobenzyl)-phenoxy]-butyric acid halide represented by the reaction of 3-hydroxy-methylpyridine and hydrochlorination of the product. . It has been found that this compound has unexpected advantageous properties as a cholesterol concentration lowering agent. It is known from GB 860,303 that aryloxycarboxylic acid esters can be used to treat elevated cholesterol and triglyside content of the blood. The compounds of the present invention are not disclosed in the above-mentioned British patent. One compound described in British Patent No. 860303, namely 2-(4'-chlorophenoxy)-isobutyric acid methyl ester (designated clofibrat by the World Health Organization), has since been It has become extremely important in human medicine. It has been found that the new compounds of the present invention are surprisingly significantly superior to clofibrate. The table below shows the results of animal experiments, which were obtained in comparison with clofibrate. Column (1) of this table contains the identification number of this test substance. The name of the test substance was written in column (2). The numbers in columns (3) and (4) are the oral dose of the test substance (mg/Kg) expressed in mg/Kg of the test animal's body weight, respectively. Column (3) lists the acute toxicity LD 50 for mice. Column (4) lists the daily dose that lowers the serum cholesterol concentration in rats by 25% (ED 25 ). Column (5) lists the therapeutic coefficient obtained from the values in the above column, ie, the quotient LD 50 /ED 25 . To determine the values in column (4), dose groups of 8 to 10 normally bred male rats were treated once daily for 10 days with the test substance suspended in gum arabic. Determination of total cholesterol content was carried out by RICHTERICH, S. Karger Basel/New York 1965, No. 232.
page). A dose-effect curve was drawn on a semi-logarithmic coordinate sheet from the percentage change in group mean values in the progressively reduced dosage formulation groups relative to the control group treated with gum arabic alone, and then the ED 25 It was read.
【表】
表から明らかな本発明の化合物の強力な低コレ
ステロール血症の作用のほかに、この化合物は血
液のトリグリセリド含量も明かに低下せしめ、こ
の点でもクロフイブラートの作用を数倍しのぐ、
このように例えばクロフイブラートは、ラツテに
於て飲用水に果糖を加えることにより惹起せしめ
た過トリグリセリド血症を85mg/Kgの経口投与量
で25％弱めたのに対して、本発明の化合物で同様
の効果を得るためには6.6mg/Kgの経口投与量が必
要であつた。
この化合物は製薬のためにそのまゝ使用するこ
とが出来る。本化合物を医薬とする場合には公知
の方法で及び慣用の助剤を使用して行なう。調剤
形式としては特にカプセル剤、錠剤又は糖衣錠
（約５ないし300mgの有効成分含量）並びに乳剤、
水剤（Losung）等を考慮する、なお治療上の目
的のためには一日の投与量として約0.002ないし
1.5ｇを服用せしめる。
例
２−メチル−２−〔４−（4′−クロルベンジル）
−フエノキシ〕−酪酸−（３−オキシメチルピリ
ジン）−エステル−塩酸塩（“Sgd33374”）
２−メチル−２−〔４−（4′−クロルベンジル）
−フエノキシ〕−酪酸クロリド78ｇ（0.232モル）
を無水ベンゼン300ml及び無水ピリジン200ml中に
溶解し、次いでこれに無水ベンゼン20ml中の３−
ヒドロキシ−メチルピリジン27ｇ（0.247モル）
の溶液を加える。この混合物を攪拌下還流温度に
５時間加熱し、次いでビユーチーロータリーエバ
ボレーター中で蒸発する。得られる褐色の残留物
をエーテルに採り、水で洗滌し、MgSO4上で乾
燥し及び減圧で蒸発する。残留物をシクロヘキサ
ン中に溶解し、これを塩基性Al2O3250ｇのカラ
ムを通す。シクロヘキサンを蒸発して得られる淡
褐色の油をエーテルに溶解し、これをエーテル中
の塩化水素溶液で処理する。結晶性の沈澱をジク
ロルメタン／エーテルより再結晶して融点111〜
114℃を有する光輝ある白色結晶として塩酸塩
40.0ｇを得る。
C24H24ClNO3・HCl（446.3）
計算値：Ｃ 64.58 Ｈ 5.65 Ｎ 3.14
Ｏ 10.75Cl 15.89
実験値： 64.95 5.65 2.98
10.46 16.00
出発原料として使用した２−メチル−２−〔４
−（4′−クロルベンジル）−フエノキシ〕−酪酸ク
ロリドは、次の様にして製造することができる：
鉱油中の55〜60％のエマルジヨンの形のナトリ
ウムヒドリド9.0ｇ（0.18モル）をジメチルホル
ムアミド（DMF）40ml中に加える。この混合物
にDMF90ml中の4′−クロル−４−ヒドロキシ−
ジフエニル−メタン39.3ｇ（0.18モル）の溶液を
ゆつくりと加える。得られた混合物を70℃に於て
15分間攪拌し、次いでDMF90ml中のエチルブロ
ムアセテート30.0ｇ（0.18モル）の溶液を加えて
130℃に７時間攪拌する。次いで溶剤をビユーチ
のロータリーエバポレーター中で除去する。残留
物を水で処理し、これをジクロルメタンで徹底的
に抽出する。抽水液は硫酸マグネシウムで乾燥し
てから減圧のもとに蒸発する。残留物をAl2O320
ｇを使用してクロマトグラフイーを行ない、ベン
ゼン200mlで洗出し及び蒸留して沸点156〜160゜
（0.03mm）を有する純粋な生成物4′−クロル−エ
トキシカルボニルメトキシ−ジフエニルメタン
（“Sgd20673”）を23.0ｇ得る
C17H17ClO3（304.8）：
計算値：Ｃ 66.98 Ｈ：5.62 Cl：11.64
実験値： 66.51 5.80 11.85
このエチルエステルも新規化合物である。この
エステルをアルコール性苛性カリ液で鹸化し及び
生成した遊離酸をチオニルクロリドでその酸クロ
リドに導びく。[Table] In addition to the strong hypocholesterolemic effect of the compound of the present invention, which is evident from the table, this compound also clearly lowers the triglyceride content of the blood, and in this respect also exceeds the effect of clofibrate several times.
Thus, for example, clofibrate attenuated hypertriglyceridemia induced by adding fructose to drinking water in rats by 25% at an oral dose of 85 mg/Kg, whereas the compounds of the present invention An oral dose of 6.6 mg/Kg was required to obtain the same effect. This compound can be used directly for pharmaceutical purposes. When this compound is used as a medicine, it can be prepared by known methods and using commonly used auxiliaries. Preparation forms include in particular capsules, tablets or dragees (with an active ingredient content of approximately 5 to 300 mg) and emulsions,
For therapeutic purposes, the daily dosage should be approximately 0.002 or
Have the patient take 1.5g. Example 2 - Methyl-2-[4-(4'-chlorobenzyl)
-Phenoxy]-butyric acid-(3-oxymethylpyridine)-ester-hydrochloride (“Sgd33374”) 2-Methyl-2-[4-(4'-chlorobenzyl)
-Phenoxy]-butyric acid chloride 78g (0.232mol)
was dissolved in 300 ml of anhydrous benzene and 200 ml of anhydrous pyridine, then this was dissolved in 3-
Hydroxy-methylpyridine 27g (0.247mol)
Add the solution. The mixture is heated under stirring to reflux temperature for 5 hours and then evaporated in a Biuchi rotary evaporator. The brown residue obtained is taken up in ether, washed with water, dried over MgSO 4 and evaporated under reduced pressure. The residue is dissolved in cyclohexane and passed through a column of 250 g of basic Al 2 O 3 . The pale brown oil obtained by evaporating the cyclohexane is dissolved in ether and treated with a solution of hydrogen chloride in ether. Recrystallize the crystalline precipitate from dichloromethane/ether to obtain a melting point of 111~
Hydrochloride salt as bright white crystals with a temperature of 114℃
Obtain 40.0g. C 24 H 24 ClNO 3・HCl (446.3) Calculated value: C 64.58 H 5.65 N 3.14
O 10.75Cl 15.89 Experimental value: 64.95 5.65 2.98
10.46 16.00 2-Methyl-2-[4 used as starting material
-(4'-Chlorbenzyl)-phenoxy]-butyric acid chloride can be prepared as follows: 9.0 g (0.18 mol) of sodium hydride in the form of a 55-60% emulsion in mineral oil are mixed with dimethylformamide. (DMF) Add to 40ml. This mixture was added with 4'-chloro-4-hydroxy-
Slowly add a solution of 39.3 g (0.18 mol) of diphenyl-methane. The resulting mixture was heated to 70°C.
Stir for 15 minutes, then add a solution of 30.0 g (0.18 mol) of ethyl bromoacetate in 90 ml of DMF.
Stir at 130°C for 7 hours. The solvent is then removed in a Biuch rotary evaporator. Treat the residue with water and extract it thoroughly with dichloromethane. The extract is dried over magnesium sulfate and then evaporated under reduced pressure. Residue Al 2 O 3 20
Chromatography was carried out using g, washing with 200 ml of benzene and distillation to give the pure product 4′-chloro-ethoxycarbonylmethoxy-diphenylmethane (“Sgd20673”) with a boiling point of 156-160° (0.03 mm). Obtain 23.0g of C 17 H 17 ClO 3 (304.8): Calculated value: C 66.98 H: 5.62 Cl: 11.64 Experimental value: 66.51 5.80 11.85 This ethyl ester is also a new compound. The ester is saponified with alcoholic potash and the resulting free acid is converted to its acid chloride with thionyl chloride.
Claims (1)
される２−メチル−２−〔４−（4′−クロルベンジ
ル）−フエノキシ〕−酪酸ハロゲニドと３−ヒドロ
キシ−メチルピリジンとを反応せしめそしてその
生成物を塩酸塩化する、２−メチル−２−〔４−
（4′−クロルベンジル）−フエノキシ〕−酪酸−（３
−オキシメチルピリジン）−エステル−塩酸塩の
製造方法。[Claims] 1. General formula [In the formula, Hal means a halogen atom. 2-Methyl-2-[4-(4'-chlorobenzyl)-phenoxy]-butyric acid halide represented by ] is reacted with 3-hydroxy-methylpyridine and the product is converted into a hydrochloride. 2-[4-
(4'-chlorobenzyl)-phenoxy]-butyric acid-(3
-oxymethylpyridine)-ester-hydrochloride production method.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1532974A CH617417A5 (en) | 1973-12-27 | 1974-11-18 | |
| CH15329/74 | 1974-11-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6140263A JPS6140263A (en) | 1986-02-26 |
| JPS6121947B2 true JPS6121947B2 (en) | 1986-05-29 |
Family
ID=4408222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5243984A Granted JPS6140263A (en) | 1974-11-18 | 1984-03-21 | Manufacture of novel cholesterol reducing compound |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS6140263A (en) |
| CH (1) | CH617656A5 (en) |
-
1979
- 1979-10-05 CH CH897879A patent/CH617656A5/en not_active IP Right Cessation
-
1984
- 1984-03-21 JP JP5243984A patent/JPS6140263A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CH617656A5 (en) | 1980-06-13 |
| JPS6140263A (en) | 1986-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2918408A (en) | Anti-spasmodic compositions specific for treating spasm of the colon | |
| NO153082B (en) | APPARATUS FOR STAPPING A WRINKED RODFORM SHEET | |
| DE2162744A1 (en) | 2-alkyl-2-alkylamino-2,6-acetoxylidides, processes for their preparation and their use | |
| DE2807623C2 (en) | 2-Phenoxyphenyl-pyrrolidine derivatives, their salts, processes for their production and pharmaceutical preparations containing them | |
| DE69427551T2 (en) | Nalbuphine esters and medicines containing them with delayed drug delivery | |
| NO152414B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2,6-DIALCOXYBENZAMIDES | |
| JPS5934695B2 (en) | Production method of new decholesterol compound | |
| CH392542A (en) | Process for the preparation of basic amides | |
| JPH0699307B2 (en) | Anti-dementia agent | |
| US2918406A (en) | Anti-spasmodics specific for peptic ulcer | |
| DE2348973B2 (en) | 1 - (m-Trifluoromethylphenyl) -4-propylpiperazine derivatives, processes for their preparation and pharmaceuticals containing these compounds | |
| CH635102A5 (en) | METHOD FOR PRODUCING NEW HETEROCYCLIC COMPOUNDS. | |
| DE2723051A1 (en) | N- (ACYL) -P-AMINO-N '- (MONOSUBSTIT.) - BENZAMIDE AND THESE MEDICINAL PRODUCTS | |
| DE1770414B2 (en) | Quinuclidine-2 and quinuclidine-3-carboxylic acid anilides, processes for their preparation and pharmaceutical compositions containing them | |
| JPS6121947B2 (en) | ||
| DE2727629C2 (en) | 1-p-Chlorobenzoyl-5-methoxy-2-methyl-3-indolyl-acetic acid-2'-phenyl-2'-carboxylic acid ethyl ester, process for its preparation and pharmaceutical agents | |
| DE2522218B2 (en) | Composition for human or veterinary medicine, methylamine derivatives and processes for their preparation | |
| DE2736268A1 (en) | NEW 5-THIAZOLE ALKYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| DE2560602C2 (en) | Oxygenated diarylamidines | |
| EP0007347B1 (en) | Alkylenglycol compounds for lowering the lipid content and processes for the preparation thereof | |
| DE2639935A1 (en) | BENZOESAEURS AND METHOD FOR THEIR PRODUCTION | |
| JP3681770B2 (en) | Treatment for senile dementia or Alzheimer's disease | |
| DE2265580C2 (en) | Heptamethyleneimino-alkyl-xanthene-9-carboxylic acid esters, their acid addition salts and processes for their preparation, as well as medicaments which contain them | |
| JPS6341392B2 (en) | ||
| DE2213044C3 (en) | Racemic and optically active 1 - (23-dichlorophenoxy) -3-tert. - butylamino-2-propanol and its salts, processes for their production and pharmaceuticals based on these compounds |